tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NGNE Stock Latest News

Promising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed
RatingsPromising Prospects for Neurogene in Rett Syndrome Treatment: Buy Rating Affirmed
17d ago
NGNE
Optimistic Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment Boosts Buy Rating
PremiumRatings
Optimistic Outlook for Neurogene’s NGN-401 in Rett Syndrome Treatment Boosts Buy Rating
17d ago
NGNE
Neurogene’s Promising Trial Design and Safety Profile Earns Buy Rating from Analyst Mitchell Kapoor
PremiumRatings
Neurogene’s Promising Trial Design and Safety Profile Earns Buy Rating from Analyst Mitchell Kapoor
17d ago
NGNE
Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating
PremiumRatings
Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating
18d ago
NGNE
Neurogene Announces Embolden Trial Design for Rett Syndrome
PremiumCompany Announcements
Neurogene Announces Embolden Trial Design for Rett Syndrome
18d ago
8K
NGNE
Neurogene says on track to share updated clinical efficacy and safety data
PremiumThe FlyNeurogene says on track to share updated clinical efficacy and safety data
18d ago
NGNE
Neurogene announces registrational trial design for Embolden study of NGN-401
Premium
The Fly
Neurogene announces registrational trial design for Embolden study of NGN-401
18d ago
NGNE
Craig-Hallum bullish on Neurogene, initiates with a Buy
Premium
The Fly
Craig-Hallum bullish on Neurogene, initiates with a Buy
1M ago
NGNE
TSHA
Neurogene initiated with a Buy at Craig-Hallum
PremiumThe Fly
Neurogene initiated with a Buy at Craig-Hallum
1M ago
NGNE
Neurogene Approves Amendments at Annual Stockholders Meeting
PremiumCompany Announcements
Neurogene Approves Amendments at Annual Stockholders Meeting
1M ago
8K
NGNE
Neurogene price target raised to $26 from $22 at BMO Capital
PremiumThe Fly
Neurogene price target raised to $26 from $22 at BMO Capital
1M ago
NGNE
Neurogene Highlights Gene Therapy Advancements in New Update
PremiumCompany Announcements
Neurogene Highlights Gene Therapy Advancements in New Update
1M ago
8K
NGNE
Neurogene Reports Q1 2025 Financial Progress and Updates
PremiumCompany AnnouncementsNeurogene Reports Q1 2025 Financial Progress and Updates
2M ago
NGNE
Optimistic Buy Rating for Neurogene Amid Favorable Market and Regulatory Conditions
Premium
Ratings
Optimistic Buy Rating for Neurogene Amid Favorable Market and Regulatory Conditions
2M ago
NGNE
Promising Outlook for Neurogene’s NGN-401 Amid Favorable Regulatory Environment and Trial Precedents
Premium
Ratings
Promising Outlook for Neurogene’s NGN-401 Amid Favorable Regulatory Environment and Trial Precedents
2M ago
NGNE
Short Report: Bears bite into Krispy Kreme after another weak earnings report
PremiumThe Fly
Short Report: Bears bite into Krispy Kreme after another weak earnings report
2M ago
RKT
DNUT
Neurogene price target raised to $22 from $16 at BMO Capital
PremiumThe Fly
Neurogene price target raised to $22 from $16 at BMO Capital
2M ago
NGNE
Neurogene announces treatment intended to reverse HLH
PremiumThe Fly
Neurogene announces treatment intended to reverse HLH
2M ago
NGNE
Cautious Hold Rating on Neurogene Due to Regulatory Uncertainty and Data Quality Concerns for NGN-401
PremiumRatings
Cautious Hold Rating on Neurogene Due to Regulatory Uncertainty and Data Quality Concerns for NGN-401
2M ago
NGNE
Neurogene downgraded to Neutral from Outperform at Baird
PremiumThe FlyNeurogene downgraded to Neutral from Outperform at Baird
2M ago
NGNE
Neurogene price target lowered to $45 from $50 at H.C. Wainwright
Premium
The Fly
Neurogene price target lowered to $45 from $50 at H.C. Wainwright
2M ago
NGNE
Neurogene’s Promising Outlook: Strategic Focus on Safety and Efficacy Justifies Buy Rating
Premium
Ratings
Neurogene’s Promising Outlook: Strategic Focus on Safety and Efficacy Justifies Buy Rating
2M ago
NGNE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >